There are two types of SCLC:
Most SCLCs are of the oat cell type.
Cancer - lung - small cell; Small cell lung cancer; SCLC
About 15% of all lung cancer cases are SCLC. Small cell lung cancer is slightly more common in men than women.
Almost all cases of SCLC are due to cigarette smoking. SCLC is rare in people who have never smoked.
SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. Although the cancer cells are small, they grow very quickly and create large tumors. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone.
Symptoms of SCLC include:
Other symptoms that may occur with this disease, especially in the late stages, include:
The doctor will perform a physical exam and ask about your medical history. You will be asked whether you smoke, and if so, how much and for how long.
When listening to your chest with a stethoscope, the doctor may hear fluid around the lungs or areas where the lung has partially collapsed. Each of these findings may suggest cancer.
SCLC has usually spread to other parts of your body by the time it is diagnosed.
Tests that may be performed include:
In most cases, a piece of tissue is removed from your lungs or other areas to be examined under a microscope. This is called a biopsy. There are several ways to do a biopsy:
Usually if a biopsy shows cancer, more imaging tests are done to find out the stage of the cancer. Stage means how big the tumor is and how far it has spread. SCLC is classified as either:
Because SCLC spreads quickly throughout the body, treatment must include cancer-killing drugs (chemotherapy) taken by mouth or injected into the body.
Treatment with both chemotherapy and radiation is done for people with SCLC that has spread throughout the body. In this case, the treatment only helps relieve symptoms. It does not cure the disease.
Radiation therapy can be used with chemotherapy if surgery is not possible. Radiation therapy uses powerful x-rays or other forms of radiation to kill cancer cells.
Radiation may be used to:
Often, SCLC may have already spread to the brain. This can occur even when there are no symptoms or other signs of cancer in the brain. As a result, some patients with smaller cancers, or who had a good response in their first round of chemotherapy may receive radiation therapy to the brain. This method is called prophylactic cranial irradiation (PCI).
Surgery helps very few patients with SCLC because the disease has often spread by the time it is diagnosed. Surgery may be done when there is only one tumor that has not spread. If surgery is done, chemotherapy or radiation therapy is still needed.
You can ease the stress of illness by joining a cancer support group. Sharing with others who have common experiences and problems can help you not feel alone.
How well you do depends on how much the lung cancer has spread. SCLC is very deadly. Not many people with this type of cancer are still alive 5 years after diagnosis.
Treatment can often prolong life for 6 to 12 months, even when the cancer has spread.
Call your health care provider if you have symptoms of lung cancer, particularly if you smoke.
If you smoke, now is the time to quit. Also try to avoid secondhand smoke.
Johnson DH, Blot WJ, Carbone DP, et al. Cancer of the lung: non-small cell lung cancer and small cell lung cancer. In: Abeloff MD, Armitage JO, Niederhuber JE, et al., eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2008:chap 76.
National Cancer Institute: PDQ Small Cell Lung Cancer Treatment. Bethesda, Md: National Cancer Institute. Date last modified 06/25/2013. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional. Accessed September 23, 2013.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Small cell lung cancer. Version 2.2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed September 23, 2013.
Reviewed By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Bethanne Black, and the A.D.A.M. Editorial team.